Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berlex Climara Pro Gains Osteoporosis Prevention Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Berlex also updates labeling for the hormone replacement therapy to include new class labeling recommended by FDA.

You may also be interested in...



Vivelle-Dot Gains Despite Flagging Hormone Therapy Market

Sometimes bigger isn’t better; Noven says that the small size of its transdermal patch may be impetus for success.

Vivelle-Dot Gains Despite Flagging Hormone Therapy Market

Sometimes bigger isn’t better; Noven says that the small size of its transdermal patch may be impetus for success.

Berlex' Angeliq Approved, Will Launch In Mid-2006

The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.

Topics

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel